Collaboration helps a young Iranian girl

Collaboration helps a young Iranian girl

Dr. Hudson Freeze and collaborators helped identify the gene mutation responsible for a little girl’s debilitating skin condition and propose a possible solution.

New hope for a rare disease

New hope for a rare disease

Dr. Yu Yamaguchi’s team developed a new model to study multiple hereditary exostoses that will help them better understand the cause of the disease and test new treatments.

Rare disease symposium has uplifting moments

Rare disease symposium has uplifting moments

Kate Fischer and daughter Morgan, who is being treated for a rare disease called hypophosphatasia, attended Sanford-Burnham’s 2nd Annual Rare Disease Day Symposium.

Studying genetic disease

The Genetic Disease Program focuses on the molecular and physiological basis of genetic disease, with a primary focus on monogenic disorders. The program's goal is to understand disease at a fundamental level, and then to use that knowledge to develop novel therapies. A hallmark of the program is collaboration with each other, with physicians, and with family support organizations. These diverse interactions provide fresh, unique insights into the potential causes of both primary symptoms and more subtle pathologies. The fruits of their basic science inform and link many scientific disciplines and medical specialties, enhancing their ability to develop new treatments and translate them into the clinic, ultimately leading to better care of patients.

In the Genetic Disease Program, each laboratory is focused on understanding and treating rare childhood disorders. Results have already been translated to patient therapies and researchers are working to discover new ones.

How our research helps improve health

Researchers in this program are developing new therapies to conquer diseases that primarily affect children, such as type 1 diabetes, congenital disorders of glycosylation, hypophosphatasia, and multiple hereditary exostoses. For example, one laboratory helped develop ENB-0040, an enzyme replacement therapy currently in clinical trials to test its effectiveness in treating hypophosphatasia, a rare inherited bone disorder similar to rickets. ENB-0040 is currently the only treatment option for the disease.

Research - Children's Health - Genetic Disease: How Our Research Helps

Recent Developments

donation

Children with rare disease CDG don’t have mutation in every cell type

Sanford-Burnham researchers discover that several children born with rare diseases called Congenital Disorders of Glycosylation (CDG) don’t contain the mutation in every cell type—raising new questions about inheritance, genomic sequencing, and diagnostics.  Read More...

Recent Publications

View All Publications
Research - Children's Health - Genetic Disease: Recent Publications
Global - Left Nav: Bottom Blue Border
Sign In Skip Navigation Links Skip navigation links
Our Mission
Research
Talent
Technology
Training & Education
Our Supporters
Privacy Policy